CoMentis Company
AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
Headquarters:
United States
Employee Number:
51-100
Technology:
Stem Cell
Industry:
Regenerative medicine
Total Funding:
$107.5M
Number Of Exists:
N/A
Investors Number:
14
Investor Type:
N/A
Founded Date:
2004
Last Funding Type:
Series E
Investment Stage:
N/A
Funding Status:
Late Stage Venture

%20.jpg)










